%0 Review
%T Primary Central Nervous System Vasculitis Following Alemtuzumab Treatment for Multiple Sclerosis: A Case Report and Literature Review.
%A Varela L
%A Pappolla A
%A Heriz A
%A Márquez R
%A Vega O
%A Christiansen S
%A Rugiero M
%A Midaglia L
%A Salerno A
%A Tintoré M
%A Rovira À
%J Neurologist
%V 28
%N 4
%D Jul 2023 1
%M 36728655
%F 1.524
%R 10.1097/NRL.0000000000000480
%X <B>BACKGROUND: </B>Cerebral vasculitides are often devastating conditions that require immediate diagnosis and treatment.<BR><B>METHODS: </B>We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition.<BR><B>CONCLUSIONS: </B>In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.